1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69(1): 7-34.
|
2. |
Chang L, Wang Y, Zhang J, et al. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. Oncotarget, 2017, 8(12): 20418-20427.
|
3. |
严律南. 中国大陆活体肝移植的现状及展望. 中国普外基础与临床杂志, 2018, 25(8): 897-899.
|
4. |
Burra P, Zanetto A, Russo FP, et al. Organ preservation in liver transplantation. Semin Liver Dis, 2018, 38(3): 260-269.
|
5. |
Voigt MR, DeLario GT. Perspectives on abdominal organ preservation solutions: a comparative literature review. Prog Transplant, 2013, 23(4): 383-391.
|
6. |
Stewart ZA. UW solution: still the “gold standard” for liver transplantation. Am J Transplant, 2015, 15(2): 295-296.
|
7. |
Erhard J, Lange R, Scherer R, et al. Comparison of histidine-tryptophan-ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantation. A prospective, randomized study. Transpl Int, 1994, 7(3): 177-181.
|
8. |
Meine MH, Zanotelli ML, Neumann J, et al. Randomized clinical assay for hepatic grafts preservation with University of Wisconsin or histidine-tryptophan-ketoglutarate solutions in liver transplantion. Transplant Proc, 2006, 38(6): 1872-1875.
|
9. |
Canelo R, Hakim NS, Ringe B. Experience with hystidine tryptophan ketoglutarate versus University Wisconsin preservation solutions in transplantation. Int Surg, 2003, 88(3): 145-151.
|
10. |
Testa G, Malagó M, Nadalin S, et al. Histidine-tryptophan-ketoglutarate versus University of Wisconsin solution in living donor liver transplantation: results of a prospective study. Liver Transpl, 2003, 9(8): 822-826.
|
11. |
Avolio AW, Agnes S, Nure E, et al. Comparative evaluation of two perfusion solutions for liver preservation and transplantation. Transplant Proc, 2006, 38(4): 1066-1067.
|
12. |
Mangus RS, Tector AJ, Agarwal A, et al. Comparison of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW) in adult liver transplantation. Liver Transpl, 2006, 12(2): 226-230.
|
13. |
Rayya F, Harms J, Martin AP, et al. Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution in adult liver transplantation. Transplant Proc, 2008, 40(4): 891-894.
|
14. |
Adam R, Delvart V, Karam V, et al. Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. Am J Transplant, 2015, 15(2): 395-406.
|
15. |
Stewart ZA, Cameron AM, Singer AL, et al. Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death. Am J Transplant, 2009, 9(2): 286-293.
|
16. |
Feng L, Zhao N, Yao X, et al. Histidine-tryptophan-ketoglutarate solution vs. University of Wisconsin solution for liver transplantation: A systematic review. Liver Transpl, 2007, 13(8): 1125-1136.
|
17. |
沙地克·阿帕尔, 吐尔洪江·吐逊, 李玉鹏, 等. UW和HTK器官保存液对移植供肝保存效果及术后结局影响的meta分析. 中华消化外科杂志, 2016, 15(5): 482-489.
|
18. |
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
|
19. |
Wells G, Shea B, Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta analysis. (2012-04-26) [2019-02-20]. http://www.o-hri.ca/programs/clinical_epidemiology/oxford.asp.
|
20. |
Kinoshita K, Ikai I, Gomi T, et al. Exposure of hepatic sinusoidal mononuclear cells to UW solution in situ but not ex vivo induces apoptosis. J Hepatol, 1998, 29(2): 300-305.
|
21. |
Hatano E, Kiuchi T, Tanaka A, et al. Hepatic preservation with histidine-tryptophan-ketoglutarate solution in living-related and cadaveric liver transplantation. Clin Sci (Lond), 1997, 93(1): 81-88.
|
22. |
Chan SC, Liu CL, Lo CM, et al. Applicability of histidine-tryptophan-ketoglutarate solution in right lobe adult-to-adult live donor liver transplantation. Liver Transpl, 2004, 10(11): 1415-1421.
|
23. |
Jain A, Mohanka R, Orloff M, et al. University of Wisconsin versus histidine-tryptophan-ketoglutarate for tissue preservation in live-donor liver transplantation. Exp Clin Transplant, 2006, 4(1): 451-457.
|
24. |
Moench C, Otto G. Ischemic type biliary lesions in histidine-tryptophan-ketoglutarate (HTK) preserved liver grafts. Int J Artif Organs, 2006, 29(3): 329-334.
|
25. |
Moray G, Sevmis S, Karakayali FY, et al. Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin in living-donor liver transplantation. Transplant Proc, 2006, 38(10): 3572-3575.
|
26. |
郑卫萍, 沈中阳, 朱志军, 等. 肝移植3种器官保存液的比较研究. 中国现代医学杂志, 2008, 18(18): 2704-2708.
|
27. |
Mangus RS, Schroering JR, Hathaway TJ, et al. Comparison of Histidine-Tryptophan-Ketoglutarate and University of Wisconsin preservation solutions in pediatric liver transplantation. Pediatr Transplant, 2018, 15: e13252.
|
28. |
Chedid MF, Pinto MA, Juchem JFG, et al. Liver preservation prior to transplantation: Past, present, and future. World J Gastrointest Surg, 2019, 11(3): 122-125.
|
29. |
Oh CK, Sawyer RG, Pelletier SJ, et al. Independent predictors for primary non-function after liver transplantation. Yonsei Med J, 2004, 45(6): 1155-1161.
|
30. |
Salviano MEM, Lima AS, Tonelli IS, et al. Primary liver graft dysfunction and non-function: integrative literature review. Rev Col Bras Cir, 2019, 46(1): e2039.
|
31. |
Moreno C, Sabaté A, Figueras J, et al. Hemodynamic profile and tissular oxygenation in orthotopic liver transplantation: Influence of hepatic artery or portal vein revascularization of the graft. Liver Transpl, 2006, 12(11): 1607-1614.
|
32. |
王正昕, 钦伦秀. 肝移植术后并发症的防治现状及进展. 中国普外基础与临床杂志, 2018, 25(9): 1025-1030.
|
33. |
蒙建源, 徐静, 樊奇, 等. 肝移植术后胆道并发症危险因素的Meta分析. 中华肝胆外科杂志, 2012, 18(11): 816-822.
|
34. |
Heidenhain C, Pratschke J, Puhl G, et al. Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transpl Int, 2010, 23(1): 14-22.
|
35. |
León Díaz FJ, Fernández Aguilar JL, Nicolás de Cabo S, et al. Combined flush with Histidine-Tryptophan-Ketoglutarate and University of Wisconsin Solutions in liver transplantation: preliminary results. Transplant Proc, 2018, 50(2): 539-542.
|
36. |
Stewart ZA, Lonze BE, Warren DS, et al. Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants. Am J Transplant, 2009, 9(5): 1048-1054.
|